Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912170 | 0.81 | ALDH1A1 (0.40) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL6639420 | 0.80 | — | — | |
| SCHEMBL29654087 | 0.80 | NPSR1 (0.35) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL5529311 | 0.79 | NPSR1 (0.41) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL9781917 | 0.79 | ALDH1A1 (0.40) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL8166868 | 0.79 | NPSR1 (0.37) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL4971017 | 0.79 | FAAH (0.39) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL30016924 | 0.76 | NPSR1 (0.36) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL11076055 | 0.75 | FAAH (0.46) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL11027876 | 0.75 | KMT2A (0.44) | NPSR1ALDH1A1POLBFAAHNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118344557-A | Diketopiperazine-based polyurethane elastomer and preparation method and application thereof | 天津科技大学 | 2024-07-16 | — | — | CN | disclosed |
| CN-105616414-B | A kind of new application of oxypiperazin amides compound | 湘北威尔曼制药股份有限公司 | 2019-03-05 | — | — | CN | disclosed |
| US-10039760-B2 | Method of using diketopiperazines and composition containing them | AMPIO PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170209433-A1 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM | DMI ACQUISITION CORP. | 2017-07-27 | — | — | US | disclosed |
| US-9561226-B2 | Method of using diketopiperazines and composition containing them | AMPIO PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20150051223-A1 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM | DMI BIOSCIENCES, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8916568-B2 | Method of using diketopiperazines and composition containing them | AMPIO PHARMACEUTICALS, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8841307-B2 | Method of using diketopiperazines and composition containing them | AMPIO PHARMACEUTICALS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130345238-A1 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM | DMI ACQUISITION CORP. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8455517-B2 | Method of using diketopiperazines and composition containing them | DMI ACQUISITION CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-4822788-A | MICROBIOCIDES, BETA-LACTAMASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| US-4782147-A | ANTIBIOTIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-11-01 | — | — | US | disclosed |
| US-4725591-A | USED WITH AMINO ACID DERIVATIVE ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| US-4675397-A | MICROBIOCIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-06-23 | — | — | US | disclosed |
| US-4665067-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| US-4550105-A | BETA-LACTAMASE INHIBITORS, ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-29 | — | — | US | disclosed |
| EP-0053815-B1 | 2-OXOAZETIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1985-05-08 | — | — | EP | disclosed |
| EP-0095764-A2 | 2-Oxoazetidinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-12-07 | — | — | EP | disclosed |
| EP-0053815-A1 | 2-Oxoazetidine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
| EP-0050965-A1 | Beta-lactamase inhibitory composition | Takeda Chemical Industries, Ltd. (JP) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345238-A1 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM | IL5, CXCL8, IL1B | NPSR1 310/4885ALDH1A1 1439/4885POLB 4170/4885 |
| US-20150051223-A1 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM | IL5, CXCL8, IL1B | NPSR1 310/4885ALDH1A1 1439/4885POLB 4170/4885 |
| US-10039760-B2 | Method of using diketopiperazines and composition containing them | IL5, CXCL8, IL1B | NPSR1 310/4885ALDH1A1 1439/4885POLB 4170/4885 |
| US-20170209433-A1 | METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM | IL5, CXCL8, IL1B | NPSR1 310/4885ALDH1A1 1439/4885POLB 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.